Belite Bio, Inc

Healthcare · Biotechnology · United States

Last price 150.28 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.05B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev...